HIV vaccine trials
Current recombinant gp120 HIV preventive vaccine candidate programs and development of other candidates currently under study should be continued, the National Institute of Allergy and Infectious Diseases AIDS Research Advisory Committee recommends at a June 17 meeting. Furthermore, the committee advises that expanded clinical trials should be pursued "when another concept and/or compelling data from current or other studies are available." ARAC made its decision after hearing presentations from NIAID's HIV Vaccine Working Group, pre-clinical and clinical research updates, feasibility research updates, public comment and remarks from Genentech and Chiron-Biocine representatives- the manufacturers of the vaccine candidates under consideration for expanded trials. In a separate statement, ARAC notes that the recommendation is only applicable to studies of the products within the U.S. The committee's recommendation will be forwarded to NIAID Director Anthony Fauci, who will render a final decision
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth